KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Operating Expenses (2018 - 2025)

Historic Operating Expenses for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $97.3 million.

  • Esperion Therapeutics' Operating Expenses rose 4376.42% to $97.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $333.2 million, marking a year-over-year increase of 1942.18%. This contributed to the annual value of $277.9 million for FY2024, which is 221.22% up from last year.
  • Per Esperion Therapeutics' latest filing, its Operating Expenses stood at $97.3 million for Q3 2025, which was up 4376.42% from $75.3 million recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Operating Expenses peaked at $97.3 million during Q3 2025, and registered a low of $60.6 million during Q3 2022.
  • Over the past 5 years, Esperion Therapeutics' median Operating Expenses value was $71.2 million (recorded in 2022), while the average stood at $72.1 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first tumbled by 3248.64% in 2021, then skyrocketed by 4376.42% in 2025.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Operating Expenses stood at $71.0 million in 2021, then fell by 13.65% to $61.3 million in 2022, then increased by 21.66% to $74.6 million in 2023, then dropped by 1.45% to $73.5 million in 2024, then skyrocketed by 32.28% to $97.3 million in 2025.
  • Its last three reported values are $97.3 million in Q3 2025, $75.3 million for Q2 2025, and $87.1 million during Q1 2025.